Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05034770
Other study ID # 2020-161
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2017
Est. completion date January 11, 2022

Study information

Verified date August 2022
Source Kocaeli University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients who were admitted to the Physical Medicine and Rehabilitation (PMR) outpatient clinic of our hospital between January 2017 and December 2020 and were treated with Major ozone autohemotherapy with a diagnosis of Fibromyalgia syndrome will include to the study. Visual anolog scale (VAS), Fibromyalgia Impact Questionnare (FIQ) and Short Form Health Survey-36 (SF-36) scores of the patients before and after treatment were recorded. Statistical analysis of these outcome scores will be made.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date January 11, 2022
Est. primary completion date January 10, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Exclusion Criteria: - has pregnancy, - has primary romatological disease, - has primary psychiatric disease - <18, >60 years old patients

Study Design


Intervention

Other:
major ozone autohemotherapy
This treatment is based on treating 100 ml of the pa- tient's blood with 100 ml of O3 followed by reinfusion in the donor, in a fast procedure. Each patient received 10 sessions of autohemotherapy with O3 twice a week.

Locations

Country Name City State
Turkey Private Medar Hospital Kocaeli

Sponsors (1)

Lead Sponsor Collaborator
Emine Dundar Ahi, MD

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Other Visual Analog Scale (VAS) The Visual Analog Scale (VAS) is usually a 100-mm long horizontal line with verbal descriptors (word anchors) at each end to express the extremes of the feeling. FM patients mark the point on the line that best corresponds to their symptom severity. To this end, they are instructed to put a cross on the straight line at the point that most accurately expresses their degree of agreement. When reading the VAS, the position of the respondent's cross is generally assigned a score between 0 and 100. If documented in paper form, the scores can then be simply transferred to a 100-value scale using a millimeter tape measure. The division into hundredths is considered suf?ciently sensitive. 10 seconds
Primary Short Form Health Survey-36 the 36-item Short Form Health Survey (SF-36) is a measure of health-related quality-of-life. It allows assessment across eight health domains: physical functioning (PF), role limitations due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH). The scores of these eight domains can also be summated in two major categories: physical composite score (PCS) and mental composite score (MCS) to reflect the overall physical and mental health, respectively. Scores of 100 for PF, RP, BP, SF, and RE domains and scores of 50 in the remaining three domains, GH, VT, and MH, indicate an absence of problems in those areas. 20 minutes
Secondary Fibromyalgia Impact Questionnare The Fibromyalgia Impact Questionnare (FIQ) is an assessment and evaluation instrument developed to measure fibromyalgia (FM) patient status, progress and outcomes. It has been designed to measure the components of health status that are believed to be most affected by FM. FIQ is scored in such a way that a higher score indicates a greater impact of the syndrome on the person. Each of the 10 items has a maximum possible score of 10. Thus the maximum possible score is 100. The average FM patient scores about 50, severely afflicted patients are usually 70 plus. 5 minutes
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05933486 - Efficacy and Safety of Tongluo-Kaibi Tablet in Patients With Fibromyalgia Syndrome Phase 4
Completed NCT01642810 - Online Acceptance-based Behavioural Treatment for Fibromyalgia Phase 3
Completed NCT00757731 - FMS European Long-Term Study Phase 3
Completed NCT00757679 - Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran Phase 2
Completed NCT01968772 - Effect of Transdermal Magnesium Chloride on Quality of Life in Patients With Fibromyalgia N/A
Completed NCT00401830 - Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome. Phase 2
Completed NCT04517929 - Effectiveness of Group Psychotherapy in Patients With Fibromyalgia Syndrome N/A
Completed NCT06285045 - Study on Roujin Formula in the Treatment of Fibromyalgia Syndrome With Blood Deficiency and Liver Depression N/A
Recruiting NCT03844412 - Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments Phase 2
Completed NCT02800720 - Meditation Awareness Training for the Treatment of Fibromyalgia Syndrome N/A
Not yet recruiting NCT01465477 - Influenza Vaccination in Fibromyalgia Patients N/A
Completed NCT00528710 - Efficacy of S-Adenosylmethionine in Fibromyalgia Phase 2
Completed NCT00447083 - Benefits of Tanning in Fibromyalgia Patients N/A
Completed NCT05381012 - Fibromyalgia Syndrome on Patients With Chronic Migraine N/A
Completed NCT00464737 - The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. Phase 2
Completed NCT04426864 - Efficacy of Different Types of Exercises in Women With Fibromyalgia Syndrome. N/A
Completed NCT02881411 - Self Soft Tissue Therapy for Fibromyalgia Syndrome N/A
Completed NCT01389336 - Add-on Complex Ayurvedic Treatment in Fibromyalgia-Syndrome Compared to Standard Care Alone N/A
Not yet recruiting NCT01147263 - Palpitations and Tachycardia in Fibromyalgia Syndrome N/A
Completed NCT00222274 - HRV Biofeedback in Fibromyalgia N/A